Arterial HypertensionNCT06769269
Hypertension Registry: Study of Primary and Secondary Hypertension Phenotypes, Complications, and Treatment Personalization.
An observational study of Arterial Hypertension, run by Moroccan Society of Cardiology at 5 sites in Morocco.
Trial summary
The quality of primary healthcare systems for patients with hypertension (HTA) in Morocco is a critical issue due to its high prevalence and significant impact on morbidity and mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arterial Hypertension
- How many people
- 10,000 participants
- Where
- 5 sitesMorocco
- Study dates
- 21 Jan 2025to 21 Jan 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients will be recruited from various public and private research centers, whether they are already under follow-up for hypertension or newly diagnosed. Various specialists will be involved in the registry to increase the diversity of recruited patients, including cardiologists, general practitioners, and nephrologists. The objective is also to identify best practices for managing hypertension.
Who may be able to join
- Individuals aged over 18 years.
- Patients with blood pressure:
- Higher than 140 mmHg systolic and/or higher or equal to 90 mmHg diastolic in consultation or in a hospital setting.
- Higher than 135/85 mmHg at home or in ambulatory blood pressure measurements (ABPM).
- Patients who have agreed and signed the informed consent.
- Patients with legal status in the Moroccan kingdom.
Who cannot join
- Patient without diagnosis of hypertension
- Patient under 18 years old
- Patients refusing to sign the informed consent.
- Patients with illegal status in the kingdom.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Morocco5 sites, 5 recruiting
- Recruiting
Moroccan Society of Cardiology
Casablanca
Mohamed ALAMI, +212661157806, cabinetalami@gmail.com
Mohamed ALAMI
- Recruiting
UM6SSP
Casablanca
Rachida HABBAL, +212661823405, habbalcardio2012@gmail.com
Rachida HABBAL
- Recruiting
Moroccan Society of Cardiology
Meknes, Morocco
Mbarek NAZZI, +2126663888, Mbarek.nazzi@gmail.com
Mbarek NAZZI
- Recruiting
Ibn Sina Hospital Center
Rabat
Nawel DOGHMI, +212661393408, doghmin@gmail.com
Nawel DOGHMI
- Recruiting
Mohamed V Military Hospital
Rabat
Najat MOUINE, +212661202733, mouine2@yahoo.fr
Najat MOUINE
About this study
The quality of primary healthcare systems for patients with hypertension (HTA) in Morocco is a critical issue due to its high prevalence and significant impact on morbidity and mortality. The concept of "quality in primary care" encompasses fundamental aspects such as timeliness, accessibility, and the provision of care based on current clinical guidelines and recommendations from professional societies.
This observational study on hypertension (HTA) uses an electronic registry accessible remotely to collect medical data from primary care and hospital settings. Investigators will be trained to ensure standardization in blood pressure measurements to minimize errors. The registry will include clinical, therapeutic, and complication data for patients aged 18 and over with a confirmed diagnosis of HTA, with information transmitted anonymously via a certified secure channel.
Read more
Informed consent from patients will be required for including their data in the registry. Collected data will include anthropometric measurements (weight, height, waist circumference, body mass index), blood pressure measurements by validated devices or ambulatory measurements, and metabolic assessments (blood glucose, total cholesterol, triglycerides, LDL, HDL, urea, creatinine, uric acid, urine albumin-to-creatinine ratio). Cardiovascular complications will also be recorded.
The study design is a cohort study with a cross-sectional perspective and a targeted follow-up period of one year. The study aims to evaluate the prevalence and phenotypes of HTA in Morocco, as well as the geographic distribution of the disease. It will compare current data with those from previous years and other North African countries to assess the applicability of Moroccan clinical practices and recommendations from the European Society of Cardiology (ESC). The goal is to enhance the understanding and management of HTA, as well as to optimize prevention and treatment strategies.
This comprehensive analysis will help identify potential gaps in primary care and develop strategies to improve the management of hypertensive patients. The comparative evaluation of data related to examinations, treatments, and complications of the cohort of patients followed for hypertension during the period 2024-2026, in comparison with results from previous years and other countries, will provide valuable insights into the shortcomings and progress in care delivery. This approach will not only identify areas needing improvement but also highlight significant advances in hypertension management.
- Conditions
- Arterial Hypertension
- Medical subject headings
- Hypertension
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of arterial hypertension
Proportion of population with arterial hypertension in Morocco.
Measured: At inclusion
To assess the distribution of HTA across the kingdom
Analyzing how arterial hypertension is spread geographically and demographically within the kingdom.
Measured: At inclusion
To analyze the various phenotypes of primary and secondary hypertension as well as the associated complications
Studying the different forms or presentations of hypertension (both primary and secondary) and their related health impacts, such as organ damage or cardiovascular events.
Measured: At inclusion
Causal relationships between Arterial Hypertension and various complications
Causal relationships between arterial hypertension and various complications such as myocardial infarction, heart failure, atrial fibrillation, renal failure, and stroke, as well as links between arterial hypertension and other secondary pathologies
Measured: At inclusion
Secondary outcomes (1)
Collect information on complications related to arterial hypertension after 1 year
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jan 2025
- Study start21 Jan 2025
- Primary completion21 Jan 2026 (estimated)
- Study completion21 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arterial HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Moroccan Society of Cardiology
- Sponsor type
- University, hospital or other
- Collaborators
- F&C Clinical Trials
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06769269
- Sponsor's protocol ID
- MoroccanSocietyCardiology
- Status last verified
- Jan 2025
- First submitted
- 6 Jan 2025
- Last updated
- 24 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No